SDHA Antibody (D-4): sc-166947
- SDHA Antibody (D-4) is a mouse monoclonal IgG2a κ, cited in 18 publications, provided at 200 µg/ml
- raised against amino acids 461-664 mapping at the C-terminus of SDHA of human origin
- recommended for detection of precursor and mature SDHA of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- m-IgG Fc BP-HRP, m-IgG2a BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for SDHA Antibody (D-4) for WB and IHC(P) applications. These reagents are now offered in bundles with SDHA Antibody (D-4) (see ordering information below).
QUICK LINKS
SDHA Antibody (D-4) is a mouse monoclonal IgG2a light chain antibody that detects succinate dehydrogenase subunit A (SDHA) in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). SDHA plays a crucial role in the mitochondrial respiratory chain, specifically in the conversion of succinate to fumarate, which is essential for aerobic respiration and energy production in cells. SDHA (D-4) antibody aids in studying SDHA′s contribution to the tricarboxylic acid cycle and electron transfer to ubiquinone, linking the citric acid cycle to oxidative phosphorylation. Mutations in SDHA can lead to severe mitochondrial disorders, including Leigh Syndrome and juvenile encephalopathy, highlighting SDHA′s importance in maintaining cellular energy homeostasis. Anti-SDHA antibody (D-4) serves as an invaluable tool for researchers studying mitochondrial function and related pathologies, providing insights into the molecular mechanisms underlying these conditions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
SDHA Antibody (D-4) References:
- Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. | Wagner, AJ., et al. 2013. Mod Pathol. 26: 289-94. PMID: 22955521
- MiR-31/SDHA Axis Regulates Reprogramming Efficiency through Mitochondrial Metabolism. | Lee, MR., et al. 2016. Stem Cell Reports. 7: 1-10. PMID: 27346679
- SDHA mutated paragangliomas may be at high risk of metastasis. | Tufton, N., et al. 2017. Endocr Relat Cancer. 24: L43-L49. PMID: 28500238
- Sdha+/- Rats Display Minimal Muscle Pathology Without Significant Behavioral or Biochemical Abnormalities. | Siebers, EM., et al. 2018. J Neuropathol Exp Neurol. 77: 665-672. PMID: 29850869
- SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2. | Burgener, AV., et al. 2019. Nat Immunol. 20: 1311-1321. PMID: 31527833
- Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis. | Li, ST., et al. 2020. Nat Metab. 2: 256-269. PMID: 32694775
- A novel de novo heterozygous pathogenic variant in the SDHA gene results in childhood onset bilateral optic atrophy and cognitive impairment. | Zehavi, Y., et al. 2021. Metab Brain Dis. 36: 581-588. PMID: 33471299
- Upregulation of SDHA inhibited proliferation, migration, and invasion of clear cell renal cell carcinoma cells via inactivation of the Wnt/β-catenin pathway. | Xu, X., et al. 2022. J Recept Signal Transduct Res. 42: 180-188. PMID: 33602019
- Flavinated SDHA underlies the change in intrinsic optical properties of oral cancers. | Marumo, T., et al. 2023. Commun Biol. 6: 1134. PMID: 37945749
- Laboratory and Genotype Relationship of Patients with SDHA-Related Mitochondrial Disease. | Civelek Ürey, B., et al. 2023. Mol Syndromol. 14: 459-460. PMID: 38058758
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SDHA Antibody (D-4) | sc-166947 | 200 µg/ml | $322.00 | |||
SDHA Antibody (D-4): m-IgG Fc BP-HRP Bundle | sc-537552 | 200 µg Ab; 10 µg BP | $361.00 | |||
SDHA Antibody (D-4): m-IgGκ BP-HRP Bundle | sc-534850 | 200 µg Ab; 40 µg BP | $361.00 | |||
SDHA Antibody (D-4): m-IgG2a BP-HRP Bundle | sc-548052 | 200 µg Ab; 10 µg BP | $361.00 |